Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin
Cell Reports · 2023-12 · 42 (12) · 113511
DOI: 10.1016/j.celrep.2023.113511 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2023-12. Verfasst von Yanguan Guo und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Biopharmacy, China Pharmaceutical University, Nanjing 211198, P.R. China; Department of General Surgery and Department of Thoracic Surgery,…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Stanford University, Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
KRAS mutations are frequently detected in non-small cell lung cancers (NSCLCs). Although covalent KRASG12C inhibitors have been developed to treat KRASG12C-mutant cancers, effective treatments are still lacking for other KRAS-mutant NSCLCs. Thus, identifying a KRAS effector that confers poor prognosis would provide an alternative strategy for the treatment of KRAS-driven cancers. Here, we show that KRAS drives expression of deubiquitinase USP13 through Ras-responsive element-binding protein 1 (RREB1). Elevated USP13 promotes KRAS-mutant NSCLC metastasis, which is associated with poor prognosis in NSCLC patients. Mechanistically, USP13 interacts with and removes the K63-linked polyubiquitination of β-catenin at lysine 508, which enhances the binding between β-catenin and transcription factor TCF4. Importantly, we identify 2-methoxyestradiol as an effective inhibitor for USP13 from a natural compound library, and it could potently suppress the metastasis of KRAS-mutant NSCLC cells in vitro and in vivo. These findings identify USP13 as a therapeutic target for metastatic NSCLC with KRAS mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biopharmacy, China Pharmaceutical University, Nanjing 211198, P.R. China; Department of General Surgery and Department of Thoracic Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632,…
- School of Biopharmacy, China Pharmaceutical University, Nanjing 211198, P.R. China.
- Department of General Surgery and Department of Thoracic Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, P.R. China.
- Department of Medical Biochemistry, Molecular Biology and Pharmacology, School of Medicine, Jinan University, Guangzhou 510632, P.R. China.
- College of Pharmacy, Jinan University, Guangzhou 510632, P.R. China.
- Medical Frontier Innovation Research Center, The First Hospital of Lanzhou University, Lanzhou 730000, P.R. China.
Förderung
- Stanford University
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
- China Pharmaceutical University
- Guangdong Provincial Natural Science Foundation
- East China Normal University
- Taishan Scholar Project of Shandong Province
Zitieren
APA
Guo, Y., Tian, J., Guo, Y., Wang, C., Chen, C., Cai, S., Yu, W., Sun, B., Yan, J., Li, Z., Fan, J., Qi, Q., Zhang, D., Jin, W., Hua, Z., & Chen, G. (2023). Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin. Cell Reports, 42(12), 113511. https://doi.org/10.1016/j.celrep.2023.113511
Vancouver
Guo Y, Tian J, Guo Y, Wang C, Chen C, Cai S, et al. Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin. Cell Reports. 2023;42(12):113511. doi:10.1016/j.celrep.2023.113511
BibTeX
@article{Guo2023,
author = {Guo, Yanguan and Tian, Jiaxin and Guo, Yongjian and Wang, Cong and Chen, Congcong and Cai, Songwang and Yu, Wenliang and Sun, Binghe and Yan, Jin and Li, Zhonghua and Fan, Jun and Qi, Qi and Zhang, Dongmei and Jin, Weilin and Hua, Zichun and Chen, Guo},
title = {Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin},
journal = {Cell Reports},
year = {2023},
volume = {42},
number = {12},
pages = {113511},
doi = {10.1016/j.celrep.2023.113511}
}
EUVIMED